Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anti-sense oligonucleotides targeted against exon 9 of IL-23R-alpha gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases

Anti-sense oligonucleotides targeted against exon 9 of IL-23R-alpha gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases

US Patent 9868776 · Granted Jan 16, 2018

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Sting agonists for treating bladder cancer and solid tumors2024
Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell 2022
Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell 2022
Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell 2022
Sting agonists for treating bladder cancer and solid tumors2021
Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-22019
Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-22019
Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-22019
Multimedia output and display device selection2019
Interactive and custom-support kiosk, methods and system2019
Pen2019
Methods and reagents that specifically detect, distinguish and quantify IFN-LAMB2018